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a b s t r a c t
Objective: Guidelines for appropriate management of vestibular schwannomas in NF2
patients are controversial. In this paper we reviewed our experience with patients with
NF2 for the results of surgical treatment with particular reference to hearing and facial nerve
preservation.
Methods: We included in the study 30 patients (16 women and 14 men) with the diagnosis of
NF2 treated in our department between 1998 and 2014 who underwent surgery for vestibular
schwannoma removal with a follow-up for at least 1 year. In 3 cases, the vestibular
schwannomas were unilateral. Six patients with bilateral vestibular schwannomas under-
went unilateral procedure. Therefore, 51 acoustic tumors were studied in 30 patients.
Results: No operative death we noted. Signiﬁcant deterioration to the non-functional level
occurred in 19 out of 22 cases with well-preserved preoperative hearing. Only three ears
maintained their preoperative good hearing. Hearing was preserved in cases of small
schwannoma not exceeding 2 cm. Among 21 patients who underwent bilateral operations
hearing was preserved in 3 out of 7 cases when smaller tumor or better hearing level side was
attempted at ﬁrst surgery. In contrary none of the 14 patients retained hearing when the ﬁrst
operation concerned the worse-hearing ear. Among 14 tumors up to 2 cm there was only one
case of moderately severe facial nerve dysfunction (House–Brackmann Grade IV) in the long
follow-up.
Conclusion: Early surgical intervention for vestibular schwannoma in NF2 patient is a viable
management strategy to maintain hearing function and preserve facial nerve function.
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Neuroﬁbromatosis type 2 is an autosomal dominant syndrome
caused by mutation of the NF2 tumor suppressor gene, located
at 22q12.2 [1,2]. The incidence is approximately one case in
25,000 live births, and the prevalence is 1 case in 100,000–
200,000 people [3]. The syndrome has the highest spontaneous
mutation rate of any human genetic disorder and approxi-
mately half of the cases represent new spontaneous muta-
tions [4]. The hallmark of this disease is the development of
bilateral vestibular schwannomas, which occurs in 90–95% of
patients [5,6]. Other central and peripheral NF2-associated
tumors include schwannomas of non-vestibular cranial,
spinal, and peripheral nerves, meningiomas, spinal ependy-
momas and optic gliomas. Moreover, patients demonstrate
non-neoplastic ocular manifestations.
This disorder is one of the most devastating and formidable
conditions with increased morbidity rates and early death.
This is due to these tumors' signiﬁcant intracranial tumor
burden and bilateral location, progressive growth despite its
histologically benign nature and the capacity to produce
further handicap by spinal cord compression.
This condition most commonly manifests itself with
hearing loss. Guidelines for appropriate management of
vestibular schwannomas in NF2 patients are controversial.
Management strategy aims to preserve hearing and facial
nerve function. Treatment options include observation,
radiosurgery, and surgery. The clinical decision regarding
the timing of the intervention is very difﬁcult. For many
neurosurgeons the risk of bilateral hearing loss secondary to
attempted surgery is the reason for the suspension of the
surgical removal of these lesions until they reach sufﬁcient
size to induce hearing loss, other cranial neuropathy, or
brainstem compression [7]. Surgical removal of the tumor,
however, only when it reaches a signiﬁcant size (watchful
waiting policy) reduces the chances of useful hearing
preservation. In this paper we reviewed our experience with
patients with NF2 for the results of surgical treatment with
particular reference to hearing and facial nerve preservation.
2. Materials and methods
2.1. Patient population
34 patients with neuroﬁbromatosis type 2, as deﬁned on the
basis of the modiﬁed National Institute of Health (NIH)
Consensus Panel Criteria [8], were surgically treated at our
institution between 1998 and 2014. We have retrospectively
reviewed the clinical records, neuroimaging studies, and
follow-up data of the treated patients. We included in the
study patients with the diagnosis of NF2 who underwent
surgery for vestibular schwannoma removal and were
observed for at least 1 year. Two patients were excluded
because they were lost to follow-up. The other two patients
were operated on due to intracranial meningioma and their
vestibular schwannomas had been treated previously at
another institution. These patients were also excluded from
the study. A total of 30 patients met the inclusion criteria andwere suitable for analysis. In 3 cases, the vestibular schwan-
nomas were unilateral. Six patients with bilateral vestibular
schwannomas underwent unilateral procedure: two patients
with the only serviceable ear, no tumor progression and
hearing stable on that side were not qualiﬁed for surgery and
the other four patients did not agree to have bilateral surgery.
Therefore, 51 acoustic tumors were studied in 30 patients. In
ﬁve patients with bilateral tumors ﬁrst vestibular schwan-
noma had been operated on at the referring institution. In 4 out
of ﬁve such cases ﬁrst operation had been non-radical. In all
cases in this subgroup, facial nerve function deteriorated to
House–Brackmann grade VI and hearing function was lost.
One of these patients was admitted to the department with
additional cranial nerve IX and X deﬁcits present after the ﬁrst
surgery. We did repeated procedure on these patients and
complete surgery was achieved in each case.
There were 16 women and 14 men in the cohort. The mean
age at the time of surgery was 25.7 years (range 13–50 years).
Tumor sizes ranged from 8 to 50 mm, with a mean of 28 mm.
The neurotological manifestations of vestibular schwanno-
mas were most commonly progressive hearing loss, tinnitus
and dizziness. The average duration of symptoms before
admission was 3.9 years. Hearing levels were measured by
pure-tone average (PTA) and speech discrimination score
(SDS) and were classiﬁed using Gardner–Robertson hearing
scale [9]. Most ears had non-serviceable hearing (Gardner–
Robertson Grade III-V) before surgery (Table 1). Pre- and
postoperative facial nerve function was assessed using the
House–Brackmann scale [10]. Two patients had Grade II and
one had Grade IV House–Brackmann function before surgery.
Our treatment philosophy assumed that the optimal
strategy for each NF2 patient is to maintain as much useful
hearing function as possible for as long lifetime as possible.
Different from non-NF2 patients the resections of vestibular
schwannomas in NF2 patients and their completeness were not
a fundamental goal of treatment in favor of extending good
quality of life period, speciﬁcally preserving unilateral hearing
at least. NF2 is not a one uniform illness but comprises several
subtypes of tumor of the brain, spinal cord and peripheral
nerves and as the spontaneous clinical course of the disease
varies from patient to patient it may need different treatment
strategies. We should always remember that treatment of
patients with NF2 necessitates surgical treatment of other than
vestibular schwannoma tumors and the need for observation of
asymptomatic tumors. Planning treatment strategies we are
guided by the principle that time of deafness should be as short
as possible. However, hearing restoration with the auditory
brainstem implants (ABIs) precludes the observation of other
tumors using MRI. This is particularly important in cases of
intramedullary tumors, which should be monitored closely.
Depend on vestibular schwannoma extension, related
necessity of brain stem decompression and preoperative
auditory function as well as the presence of symptomatic
intracranial meningioma and/or spinal tumors, the surgical
strategy i.e., the indication, the order of tumors removal and
the timing of tumor resection should be planned individually
in each patient. In some cases treatment was started with the
removal of other symptomatic tumors (likewise non-vestibu-
lar schwannoma, intracranial meningioma or spinal tumor) or
these tumors were attempted in second stage after surgery of
Table 1 – Postoperative hearing results as a function of the preoperative hearing status.
Preoperative hearing statusa No. of cases
Postoperative hearing statusa
I II III IV V Total
I 2 1 3 3 3 12




Total 2 1 4 5 39 51
a According to Gardner–Robertson scale.
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tumor surgery had to be postponed. In case of asymptomatic
but large spinal tumor of the cervical region our management
strategy was to start with spinal cord decompression. In cases
where spinal canal tumor was found that required observa-
tion, brainstem or cochlear implant assumption was post-
poned until control MRI evaluation of any tumor growth was
performed.
The surgical management of intracranial meningiomas
and spinal tumors in NF2 patients will be presented in a
separate paper.
One of the management options was the surgical resection of
the larger tumor with dead ear or non-serviceable hearing with
subsequent auditory brainstem implant implementation to
assist learning of a new type of auditory function by still hearing
ear on the side of a smaller tumor. Preoperatively some patients
had useful hearing preserved on both sides. In some of them the
ﬁrst operation was performed on the smaller tumor and better-
hearing ear. In the remaining patients, treatment was initiated
at larger tumor and worse-hearing ear. When hearing has been
preserved at the ﬁrst operation the next stages of treatment
become easier. If surgery on the ﬁrst side with preoperative
serviceable hearing was performed with subsequent loss of
auditory function then auditory brainstem implant was used. In
most cases ABI procedure was performed during second side
vestibular schwannoma resection when it came to total
deafness. For patients with bilateral hearing loss who had
intact cochlear nerve, cochlear implant for auditory rehabilita-
tion was offered. Our experience in applying the ABI procedure
is presented in the subsequent work.
2.2. Surgical approach
In 46 cases retrosigmoid approach was used and 2 ears of
patients were treated via a translabyrinthine approach. Three
cases of small tumor did undergo middle fossa excision as the
ﬁrst step of treatment. Intraoperative facial nerve monitoring
was used in all cases. Hearing function was monitored
intraoperatively using auditory brainstem response (ABR)
assessments or transtympanic electrocochleography (TT-
ECochG) in selected cases of preoperatively serviceable hearing.
2.3. Patient's follow-up
The scope of resection was evaluated based on the intraop-
erative observation and the result of postoperative brainmagnetic resonance imaging (MRI). Postoperative hearing data
and facial nerve function were obtained on discharge from
hospital and at follow-up hospital stay one year after
operation. The postoperative follow-up period ranged from
18 months to 15 years (mean 5.3 years).
3. Results
3.1. Operative results
Total or near-total tumor removal was obtained in all cases, as
conﬁrmed by postoperative MRI. Schwannoma diagnosis was
established based on tumor histopathology. In four cases
tumor histology revealed mixed type of tumor (schwannoma
plus meningioma).
No operative death we noted. In six patients with extremely
large tumors new postoperative paresis in previously normal
cranial nerves IX and X occurred and two of these patients
required temporary tracheotomy and percutaneous endoscop-
ic gastrostomy (PEG). Cranial nerves IX and X palsy, however,
subsided in three patients and signiﬁcantly diminished in the
other three during follow-up. A new abducens nerve deﬁcit
occurred in 2 patients and proved permanent. Five patients
suffered from postoperative cerebellar ataxia but showed
gradual improvement in the follow-up. One patient required
ventriculo-peritoneal shunt placement because of the hydro-
cephalus development in the postoperative course. Two
patients experienced a cerebrospinal ﬂuid leak which was
resolved with lumbar drainage.
3.2. Hearing preservation
Signiﬁcant deterioration to the non-functional level occurred
in 19 out of 22 cases with well-preserved preoperative hearing.
Only three ears maintained their preoperative good hearing.
Hearing was preserved in cases of small schwannoma not
exceeding 2 cm. Tables 1 and 2 present postoperative hearing
results for the preoperative hearing level and different tumor
size groups.
Among 21 patients who underwent bilateral operations the
ﬁrst operation on vestibular schwannoma was performed on
the side of larger tumor in 14 patients and on the smaller
tumor in 7 cases. The auditory function was then preserved in
3 patients and in 3 other patients the cochlear nerve was
preserved anatomically. In 4 patients ABI operation was
Table 4 – Postoperative hearing results as a function of surgery timing after vestibular schwannoma diagnosis.




I II III IV V Total
≤6 months 2 1 3 1 18 25
>6 months ≤ 1 year 1 2 8 11
>1 year ≤ 2 years 2 4 6
>2 years 9 9
Total 2 1 4 5 39 51
a According to Gardner–Robertson scale.
Table 2 – Postoperative hearing results as a function of the preoperative tumor size.
Preoperative tumor size (mm) No. of cases
Postoperative hearing statusa
I II III IV V Total
≤10 1 1
>10 ≤ 20 2 4 1 5 12
>20 ≤ 30 3 13 16
>30 1 20 21
Total 2 1 4 5 39 51
a According to Gardner–Robertson scale.
Table 3 – Hearing preservation in 21 patients operated on for bilateral vestibular schwannoma depending on the first
attempted tumor side.
First attempted tumor side No. of patients
Serviceable hearing Non-serviceable hearing Total
Smaller tumor and/or better hearing status 3 4 7
Larger tumor and/or worse hearing status 0 14 14
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surgery was performed with subsequent loss of hearing in
each case and cochlear nerve preservation was achieved only
in one case. In 11 patients ABI was inserted in the second stage
of the procedure. One patient had bilateral ABI insertion.
In summary, in the group of 21 patients operated on both
sides 3 patients preserved hearing on one side, 4 patients had
cochlear nerve preserved unilaterally and 14 patients under-
went ABI insertion. In 4 patients who had some measurable
hearing postoperatively and conﬁrmed eighth cranial nerve
preservation by an intraoperative monitoring, cochlear
implants were inserted in the next step. Hearing preservation
was noted only when smaller tumor and better hearing level
side was attempted at ﬁrst surgery (Table 3). There was
signiﬁcant relationship between surgery timing and the ability
to preserve hearing: better results were obtained when
patients were treated within 6 months of the diagnosis of
vestibular schwannoma (Table 4).
In all three patients with unilateral vestibular schwannoma
hearing function of the affected ear was lost after surgery. Of
the 6 patients with bilateral tumors who underwent only
unilateral operations, in 4 cases ear was dead preoperatively
and in two other patients hearing was lost after surgery; in 2
patients ABI surgery was performed. Four patients from thissubgroup exhibited progressive hearing loss on the second
side but refused surgical procedure and the other two still
retain useful hearing and are being monitored.
3.3. Facial nerve function
Immediately after surgery facial nerve function was normal in
2 cases. In 19 cases postoperative facial nerve function was
moderately impaired (Grade II and III on the House–Brack-
mann scale) and early rehabilitation of the nerve was
introduced. In another 19 cases facial nerve function was
Grade IV and the eye was protected with a humid chamber.
Anatomical continuity of the facial nerve was not compro-
mised in any of these cases as conﬁrmed by intraoperative
facial nerve monitoring and patients showed gradual im-
provement of the nerve function during postoperative
rehabilitation. In 8 out of 11 cases with severe postoperative
facial nerve palsy (Grade V and VI) a golden plate had been
implanted into the upper lid in the early postoperative period
in order to facilitate eye closure and then hemihypoglossal-
facial nerve anastomosis was performed usually 1 month after
tumor removal. Facial nerve function after the anastomosis
procedure was satisfactory in all but one case. In another case
a facial plastic surgery was performed because of long-lasting
Table 5 – One year postoperative facial nerve function as a function of the preoperative tumor size.
Preoperative tumor size (mm) No. of cases
Postoperative facial gradea
I II III IV V VI Total
≤10 1 1 2
>10 ≤ 20 5 3 3 1 12
>20 ≤ 30 10 4 2 16
>30 1 4 11 3 2 21
Total 7 18 18 4 0 4 51
a According to House–Brackmann scale.
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operation had been performed at another institution and the
facial nerve was then permanently damaged underwent there
tarsorrhaphy and were not qualiﬁed for restoration of facial
nerve continuity.
Long-term facial nerve function results are shown in
Table 5.
Among 14 tumors up to 2 cm there was only one case of
moderately severe facial nerve dysfunction (House–Brack-
mann Grade IV) in the long follow-up. On the other hand we
achieved unsatisfactory results of facial nerve preservation
(House–Brackmann Grade IV-VI) in 8 out of 37 larger tumors
exceeding 2 cm.
3.4. Tumor recurrence
There was vestibular schwannoma recurrence in 5 cases.
Median time to recurrence was 8.8 years (range 5–14 years).
Tumor recurrence was noted in 3 patients. In two patients
there was bilateral tumor regrowth: one patient is qualiﬁed for
second surgery of the two tumors and the other patient
underwent complete re-surgery on one side and remains
asymptomatic while observing a second side small tumor
regrowth. The third patient who had undergone unilateral
procedure refused surgery both for the second side progressive
tumor growth as well as for tumor recurrence after ﬁrst
surgery.
4. Discussion
4.1. Treatment options and hearing preservation
Neuroﬁbromatosis type 2 (NF2) is a heritable tumor predispo-
sition syndrome that leads to the development of multiple
intracranial tumors. The pathognomonic lesion of NF2 is
vestibular schwannoma appearing bilaterally. In this retro-
spective study we examined the cases of 30 adolescents and
adults with NF2 who had undergone vestibular schwannoma
surgery. The main goal of treatment in patients with this
condition in view of the danger of bilateral deafness with its
serious consequences is to preserve as much hearing as
possible which is a tremendous advantage in the quality of the
patients' life. This is especially important because of the young
age of the NF2 patients and knowing that these tumors will
continue to grow over time [11,12]. Early detection of NF2
allows those individuals with small tumors and useful hearingthe advantage of greater ability to preserve hearing. Better
preoperative hearing is related to better postoperative hearing
[13–15]. Unfortunately, in our series nearly 60% of ears had
non-serviceable hearing and only 4% of tumors did not exceed
1 cm preoperatively. Thus, hearing was preserved in only 3
cases. Slattery et al. [13] reported that difference in average
tumor size between the groups in which hearing was
preserved was 0.6 cm. In their study hearing was preserved
in 55% of cases, however, most patients (81%) had very good
hearing before surgery. On the basis of their results Brack-
mann et al. [11] proposed that early surgical intervention for
patients with vestibular schwannomas and NF2 may prevent
the occurrence or progression of hearing loss. Similarly, Sami
et al. [16] advocate for active management strategy of early
surgery in patients who have NF2 if the chances of functional
hearing preservation are realistic. In patients with similar
tumor sizes their recommendation for surgery depends on the
superior quality of preoperative ABR on one side, as the
chances of successful hearing preservation are better on that
side. It should be noted that besides tumor size and
audiometric data, patient's preoperative ABR is very important
predictive factor for the auditory outcome. Tumor parameters
inﬂuencing the chances of hearing preservation such as tumor
consistency and adhesion at the tumor plane and the fundus
of the internal auditory canal might be obtained by the
patient's ABR [17].
The policy of proactive surgical management of these
tumors assumes that given the beneﬁts of preserving useful
auditory function on at least one side, the decision about
surgery on the side of better hearing is worth taking, despite
the risk of reduced postoperative quality of life in case of
hearing lost. Described above philosophy of treating vestibular
schwannomas in NF2 patients is contrary to the traditional
approach of withholding intervention from this patient group
either the tumor enlarges signiﬁcantly or the patient becomes
symptomatic [7]. So-called watchful waiting policy points that
the majority of NF2 intracranial tumors including vestibular
schwannomas grow in a ‘‘saltatory’’ pattern, with periods of
growth alternating with quiescent periods [18]. In this
approach these tumors should not be surgically treated simply
because they exist, as they may not grow for considerable
periods of time [19,20]. Dirks et al. [18] analyzed the rate of
growth and the growth pattern of various intracranial tumors
in NF2 patients and recommend to operate only on tumors
that are progressively symptomatic. In their opinion tumor
progression alone, without the development of progressive
symptoms, should not be used as an indication for surgery.
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asymptomatic tumors will lead to additional unnecessary
surgeries over a deﬁnite period of time. Similarly, Peyre et al.
[19] reported unpredictable vestibular schwannoma growth
rates in NF2 patients, lack of correlation between growth rates
and hearing outcome and demonstrate that most patients
preserve some degree of hearing and most tumors grow slowly
in approximately 5-year follow-up. It seems, however, that in
case of vestibular schwannoma this approach reduces the
chances of long-term hearing preservation. Many patients can
initially avoid surgical intervention but looking at the long
term with tumors growing slowly and hearing worsening
gradually they end up facing surgical treatment with little
chance of good hearing outcome. Nevertheless, observation
without surgical procedure might be useful option for patients
with non-serviceable hearing or who have a tumor in their
only hearing ear [21].
Another option for the treatment of NF2 is stereotactic
radiosurgery. This treatment modality is proposed for small
and middle-sized tumors. Radiosurgery eliminates many of
the risks of resection [22]. Recent radiosurgical series of
patients with NF2 reported the hearing preservation rate of
67% and the actuarial tumor control rate of 67% at 5 years
[23,24]. NF2-associated intracranial tumors, however, both
schwannomas and meningiomas, seem to be less sensitive to
stereotactic radiosurgery than their sporadic counterparts [18].
Another drawback of radiosurgery is the inability to provide
brainstem decompression in patients with large tumors who
have signiﬁcant symptoms from compression.
4.2. Auditory rehabilitation
In our series complete bilateral hearing loss was frequent
consequence of vestibular schwannoma management. 20
patients were offered auditory brain implants or cochlear
implants which are options for hearing remediation. Auditory
rehabilitation becomes a signiﬁcant aspect in the care of
patients with NF2 because most of them will lose hearing
bilaterally. Hearing aids are usually less effective in NF2 cases
because speech discrimination in these patients has been
compromised and they require implanted devices for hearing
improvement. Vestibular schwannomas frequently destroy
the cochlear nerve and auditory rehabilitation in these
individuals relies on auditory brainstem implants (ABIs)
which bypass the external, middle, and inner ear and directly
stimulate the cochlear nucleus. Placement of the ABIs have
the potential to recover some degree of auditory perception,
however, it is rarely adequate for speech understanding and
mainly serve to enhance lip reading [25,26]. Nevertheless
Matthies et al. [27] have reported recently that open-set
speech recognition in pure auditory mode is feasible in
patients with ABIs. In case of an intact cochlear nerve
following vestibular schwannoma removal alternative strat-
egy to restore hearing is cochlear implantation. Cochlear
implants directly stimulate the cochlear nerve within the
cochlea and typically result in open-set speech recognition
and ability to converse by telephone [28,29], thus improving
social and professional functioning. This suggests that there
will be an increasing role for cochlear implantation in hearing
rehabilitation.4.3. Facial nerve function
Preservation of facial nerve function is critical in NF2 patients
for social and quality of life reasons. The level of facial
function preservation was satisfactory in the study group and
was obviously related to the tumor size. Anatomic preserva-
tion of the facial nerve is the primary goal of vestibular
schwannoma treatment both for NF2 patients as well as for
patients with sporadic tumors. Facial nerve continuity is to be
compromised in various situations [14]. The facial nerve could
be lost in previous surgery that was performed elsewhere. In
case of circumscribed schwannoma resection usually led to
facial nerve discontinuity. Sometimes there could be no
cleavage plane between the vestibular, cochlear, and facial
nerves and the facial nerve continuity could be easy lost in
these cases. Besides, the facial nerve could also show
tumorous changes. In the case of permanent damage to the
facial nerve it should be reconstructed intracranialy at the
cerebellopontine angle by sural grafting, reanimated by
hemihypoglossal-facial anastomosis or patient should un-
dergo facial plastic surgery [30–33].
5. Conclusions
Clinical decision regarding when to operate on NF2 patients
with vestibular schwannomas relay on the realistic chances of
hearing preservation. It seems that the initiation of treatment
from small tumors with preserved hearing offers the best
chance of hearing preservation. In this situation, it is safe to
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